Position: Board member (since 23 April 2026)
Number of shares in Navamedic ASA: 0
Other current directorships: GG Ventures, MagCath ApS, Biobridge Partners and Fluoguide A/S
Year of birth: 1969

Experience:
Camilla Harder Hartvig has 30 years of operational and strategic commercial experience within the worldwide lifescience industry. She has lived abroad for most of her career, only returning to Denmark in 2023. Her most recent roles were as EVP, CCO in Ascendis Pharma in Copenhagen; EVP, CCO in Theramex Ltd based in London and before that SVP for the International region in Alexion Pharmaceuticals based out of Zurich. Camilla has led numerous product launches worldwide, most notably as the VP Global Marketing for AstraZeneca. Camilla has served on boards for more than a decade, in leading companies like Danish Crown A/S and CWorldWide.

Education:
Camilla holds a MBSc in Economics and Business Administration – International marketing and management from CBS, a CEMS MIM from HEC in Paris and board educations from Harvard and INSEAD.